Fig. 6

Schematic diagram of the mechanism of ICL participating in the regulation of the occurrence and progression of LC in patients with COPD. The right frame illustrates a continuously activated hsa-miR19-3p/NKRF/ NF-κB circular regulatory pathway which leads to the occurrence and progression of LC in COPD patients. The left frame illustrates a proposed model of ICL in inhibiting the occurrence and progression of LC in COPD patients by blocking hsa-miR19-3p/NKRF/NF- κ B pathway